Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on SGLT 2 Inhibitors. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN117186035A details a high-yield synthesis for empagliflozin intermediates. Discover cost-effective manufacturing and reliable supply chain solutions for pharmaceutical production.
Patent CN102046645B details a one-pot synthesis for high-purity spiroketal derivatives. This method ensures supply chain stability and cost reduction in API intermediate manufacturing.
Patent CN111269205B details a robust Pd-catalyzed method for C-aryl glycosides, offering high stereoselectivity and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN109988161A details a telescoped synthesis for Empagliflozin, offering significant cost reduction in API manufacturing and enhanced supply chain reliability for global buyers.
Novel Pummerer reaction method for sulfur-containing aryl carbon glycosides. Mild conditions, high yield, suitable for API intermediate manufacturing.
Patent CN113801010A reveals a high-yield route for 5-bromo-2-chlorobenzoic acid, a key SGLT2 inhibitor intermediate, offering superior purity and supply chain stability.
Patent CN114933619A discloses potent thioglycoside analogs with nanomolar IC50. Streamlined Pd-catalyzed synthesis offers cost-effective pharma intermediate supply.
Patent CN110002989B reveals a high-selectivity synthesis for 5-bromo-2-chlorobenzoic acid, offering cost reduction and superior purity for SGLT-2 inhibitor manufacturing.
Novel dibromo-amino silica gel method achieves >99% selectivity and >99.8% purity for SGLT-2 inhibitors, significantly reducing waste and manufacturing costs.
Novel one-pot method for (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone. High purity, reduced steps, eco-friendly process for API manufacturing.